Your browser doesn't support javascript.
loading
Sickle Cell Disease and Gene Therapy - Patient and Physician Perspectives.
DeBaun, Michael; Heeney, Matthew; Jackson, Terry; Longo, Dan; Love, Melesa; Love, Trinity; Okwo, Phillip; Thompson, Alexis; Trimnell, Cassandra; Woolford, Teonna.
Afiliação
  • DeBaun M; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Heeney M; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Jackson T; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Longo D; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Love M; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Love T; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Okwo P; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Thompson A; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Trimnell C; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
  • Woolford T; From the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Nashville, TN (M.D.); the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Sickle Cell Program, Boston (M.H.); the Division of Hematology, Children's Hospital of Philadelphia, Philadelphia (A.T.); Sickle Cell 1
N Engl J Med ; 387(13): e28, 2022 09 29.
Article em En | MEDLINE | ID: mdl-36170507

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / Atitude do Pessoal de Saúde / Atitude Frente a Saúde / Anemia Falciforme Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Genética / Atitude do Pessoal de Saúde / Atitude Frente a Saúde / Anemia Falciforme Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article